Roivant Sciences Ownership
| ROIV Stock | USD 11.44 0.21 1.80% |
Shares in Circulation | First Issued 2020-06-30 | Previous Quarter 722.7 M | Current Value 707.3 M | Avarage Shares Outstanding 723.2 M | Quarterly Volatility 46.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roivant Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. Roivant Stock Ownership Analysis
About 30.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.66. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Roivant Sciences recorded a loss per share of 0.75. The entity had not issued any dividends in recent years. Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 863 people. To find out more about Roivant Sciences contact Matthew Gline at 44 20 7400 3347 or learn more at https://roivant.com.Besides selling stocks to institutional investors, Roivant Sciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Roivant Sciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Roivant Sciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Roivant Sciences Quarterly Liabilities And Stockholders Equity |
|
Roivant Sciences Insider Trades History
About 30.0% of Roivant Sciences are currently held by insiders. Unlike Roivant Sciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Roivant Sciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Roivant Sciences' insider trades
Roivant Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Roivant Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Roivant Sciences backward and forwards among themselves. Roivant Sciences' institutional investor refers to the entity that pools money to purchase Roivant Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2025-03-31 | 9.9 M | Geode Capital Management, Llc | 2025-03-31 | 8 M | Ubs Group Ag | 2025-03-31 | 6.8 M | Woodline Partners Lp | 2025-03-31 | 5.3 M | Anchorage Advisors, Llc | 2025-03-31 | 4.8 M | Blackbarn Capital Partners Lp | 2025-03-31 | 4.8 M | Norges Bank | 2024-12-31 | 4.4 M | Toms Capital Investment Management Lp | 2025-03-31 | 4.1 M | Bank Of New York Mellon Corp | 2025-03-31 | 4 M | Qvt Financial Lp | 2025-03-31 | 65.8 M | Sb Investment Advisers (uk) Ltd | 2025-03-31 | 61.9 M |
Roivant Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Roivant Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Roivant Sciences Outstanding Bonds
Roivant Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Roivant Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Roivant bonds can be classified according to their maturity, which is the date when Roivant Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Roivant Sciences Corporate Filings
F4 | 1st of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 25th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.